No files uploaded.
Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it intends to expand the scope of its sponsored research in Nigeria to include neurological conditions, including Post-Traumatic Stress Disorder (PTSD). CBIS and its research collaborator are currently investigating the potential beneficial effects of cannabidiol on oro-bucco-lingual dyskinesias, oxidative stress, and psychosis using animal studies and a clinical trial.
See the full press release here;
Great read and movement in the industry blog.norml.org/2019/06/20/congress-votes-yes-to-pr…Loading content, please wait.
As more states are legalizing the use of cannabis for medicinal reasons in hopes to eradicate deaths associated with opioid use, New Mexico added...CBIS Fights to End Opioid Deaths Campaign